Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity – two common nerve agents
Nexien BioPharma was granted patent for “Use of Cannabinoids and Terpenes for Treatment of Organophosphate and Carbamate Toxicity” by the Israeli Patent Office.
@BiondVax Pharmaceuticals has enrolled first participants in the second cohort of the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal #flu #vaccine candidate.
Teva Presents Positive Results Showing Improvement in Disability and Quality of Life from the Phase IIIb FOCUS study of Fremanezumab in Adults with Migraine
These results include reduction in monthly average migraine days; reduction in migraine related symptoms; and improvements in depression status; work productivity and activity impairment.
Takeda Selects Five New Partnerships for Annual Global Corporate Social Responsibility (CSR) Program
Takeda’s founding mission to serve patients, wherever they are, drives its increased commitments to disease prevention, capacity building, and access to healthcare in developing and emerging countries, in partnership with the global community.
Euromed, a Spain-based producer of standardized herbal extracts and natural active substances for pharmaceutical, nutraceutical and cosmetic industries, said Wednesday that, according to a recently published randomised, double-blind, placebo-controlled study, supplementation with Euromed’s natural extracts Pomanox™ and Mediteanox™ could help to maintain a healthy blood pressure, endothelial function and levels of circulating oxidised low-density lipoprotein cholesterol (oxLDL).
Teva to present new fremanezumab FOCUS Clinical Study Data for the first time at the 13th European Headache Federation Congress
Teva presents 17 posters and three oral presentations at EHF 2019 highlighting long-term and FOCUS Phase IIIb study data The
Ayala Pharmaceuticals’ preclinical data supports clinical development of AL101 in TripleNegative Breast Cancer (TNBC) tumors bearing Notch mutation
– Ongoing Phase 2 ACCURACY study to explore AL101 and its effect on tumor growth inhibition in people with Adenoid
The global pulmonary embolism therapeutics market is expected to post aCAGR of more than 9% during the period 2019-2023, according to thelatest market research report by Technavio.
The traditional R&D in the biopharmaceutical industry iswitnessing an upsurge, due to drug development research, which ishelping in the augmentation of the industrial microbiology market.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) todayannounced the launch of a generic version of Delzicol®1(mesalamine) delayed-release capsules, 400 mg, in the U.S.